InterShunt Technologies has enrolled its first patient in an early feasibility study evaluating its novel device for treating heart failure with reduced ejection fraction (HFrEF).
Dr. Sitaramesh Emani and the Structural Heart Intervention Team at The Christ Hospital Health Network in Cincinnati performed the first procedure. The InterShunt device creates a small opening between the heart’s upper chambers, lowering elevated left atrial pressure to reduce heart failure symptoms and improve quality of life.
Unlike other approaches, the proprietary catheter system mechanically cuts a precise piece of tissue to create an atrial shunt without leaving any permanent implant, minimizing scarring and maintaining natural heart movement.
“Our first patient went home the next day feeling well,” said Dr. Emani. “We’re hopeful this will help many more people.” CEO Harlee Sorkin added: “This milestone keeps future treatment options open while avoiding risks of permanent implants.”
Follow MEDWIRE.AI for the latest updates in heart failure treatment innovation.
